Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Enterprise ValueMarket Capitalization

Immuneering (IMRX) EBIT Margin: 2020-2022

Historic EBIT Margin for Immuneering (IMRX) over the last 3 years, with Dec 2022 value amounting to -3,073,627.91%.

  • Immuneering's EBIT Margin fell 306776489.00% to -3,073,627.91% in Q4 2022 from the same period last year, while for Dec 2022 it was -16,325.77%, marking a year-over-year decrease of 1469661.00%. This contributed to the annual value of -16,325.77% for FY2022, which is 1469661.00% down from last year.
  • Latest data reveals that Immuneering reported EBIT Margin of -3,073,627.91% as of Q4 2022, which was down 8,844.84% from -34,362.04% recorded in Q3 2022.
  • Immuneering's EBIT Margin's 5-year high stood at -644.66% during Q3 2020, with a 5-year trough of -3,073,627.91% in Q4 2022.
  • Its 3-year average for EBIT Margin is -285,384.79%, with a median of -1,772.01% in 2021.
  • Data for Immuneering's EBIT Margin shows a maximum YoY slumped of 306,776,489bps (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows Immuneering's EBIT Margin stood at -877.56% in 2020, then crashed by 498,546bps to -5,863.02% in 2021, then tumbled by 306,776,489bps to -3,073,627.91% in 2022.
  • Its EBIT Margin was -3,073,627.91% in Q4 2022, compared to -34,362.04% in Q3 2022 and -12,334.43% in Q2 2022.